Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept
Changes in serum cartilage oligomeric matrix protein (COMP) were studied during a 6-month period from initiation of treatment of rheumatoid arthritis patients with either infliximab or etanercept, to elucidate whether the favourable results of tissue protection reported in clinical trials are corrob...
Збережено в:
| Опубліковано в:: | Arthritis Res Ther |
|---|---|
| Автори: | , , , , , |
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMC
2003
|
| Предмети: | |
| Онлайн доступ: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC165057/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12823852/ https://ncbi.nlm.nih.govhttps://doi.org/10.1186/ar760 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|